Shanghai Medical College

Company snapshot

Shanghai Medical College of Fudan University is a hospital & health care company based out of United Kingdom.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai Medical College. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Shanghai Medical College.

1. May 26, 2026 Clinical update

   tissue-of-origin (ORIGIN-PanCA○R) profiling — Phase 3

2. May 26, 2026 Clinical update

   EOF5 — Phase 2

3. May 26, 2026 Clinical update

   IGEV — Phase 2

4. May 26, 2026 Clinical update

   anlotinib — Phase 2

View all clinical trial activity →

• What is Shanghai Medical College?

  Fudan University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Extensive-stage Small Cell Lung Cancer, Gastric Cancer, Hodgkin Lymphoma, Cancer of Unknown Primary Site. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 pa

• Is Shanghai Medical College publicly traded?

  Shanghai Medical College appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai Medical College develop or market?

  We link 3 drug profile(s) where Shanghai Medical College is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/fudan-university#company-drugs.

• What are the latest developments for Shanghai Medical College?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai Medical College focus on?

  Shanghai Medical College focuses on Extensive-stage Small Cell Lung Cancer, Gastric Cancer, Hodgkin Lymphoma based on our analysis of their pipeline programs and drug development activities.